WO2010118367A3 - Pyrimidines antivirales - Google Patents

Pyrimidines antivirales Download PDF

Info

Publication number
WO2010118367A3
WO2010118367A3 PCT/US2010/030598 US2010030598W WO2010118367A3 WO 2010118367 A3 WO2010118367 A3 WO 2010118367A3 US 2010030598 W US2010030598 W US 2010030598W WO 2010118367 A3 WO2010118367 A3 WO 2010118367A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
infection
pyrimidines
pyrazolopyrimtdines
virus
Prior art date
Application number
PCT/US2010/030598
Other languages
English (en)
Other versions
WO2010118367A2 (fr
Inventor
Amy Qi Han
Eric Wang
Carla Gauss
Walter Xie
Glen Coburn
Jean-Marc Demuys
Original Assignee
Progenics Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharmaceuticals, Inc. filed Critical Progenics Pharmaceuticals, Inc.
Publication of WO2010118367A2 publication Critical patent/WO2010118367A2/fr
Publication of WO2010118367A3 publication Critical patent/WO2010118367A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La présente invention concerne de nouveaux composés comprenant des pyrimidines, des pyrazolopyrimidines, et des imidazolopyrimidines substituées, leurs synthèses, et des compositions les comprenant, y compris des compositions pharmaceutiques, comprenant les nouvelles pyrimidines, pyrazolopyrimidines, imidazolpyrimidines et des composés analogues. De tels composés fonctionnent en inhibant l'entrée des virus de la famille des Flaviviridae, y compris le virus de l'hépatite C (VHC), à l'intérieur des cellules qui sont susceptibles d'être infectées par les virus. Ces composés sont utiles dans le traitement, la thérapie et/ou la prophylaxie de maladies virales et d'infections, y compris l'infection par le VHC.
PCT/US2010/030598 2009-04-10 2010-04-09 Pyrimidines antivirales WO2010118367A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16832309P 2009-04-10 2009-04-10
US61/168,323 2009-04-10

Publications (2)

Publication Number Publication Date
WO2010118367A2 WO2010118367A2 (fr) 2010-10-14
WO2010118367A3 true WO2010118367A3 (fr) 2011-03-10

Family

ID=42936895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/030598 WO2010118367A2 (fr) 2009-04-10 2010-04-09 Pyrimidines antivirales

Country Status (1)

Country Link
WO (1) WO2010118367A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845856A1 (fr) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones en tant qu'inhibiteurs de PI3K
US8445490B2 (en) 2009-10-14 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN102656174A (zh) 2009-10-14 2012-09-05 百时美施贵宝公司 用于治疗丙型肝炎的化合物
WO2011075643A1 (fr) 2009-12-18 2011-06-23 Incyte Corporation Dérivés condensés d'hétéroaryles substitués à titre d'inhibiteurs de pi3k
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US8741884B2 (en) 2010-05-04 2014-06-03 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US8765944B2 (en) 2010-08-19 2014-07-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US9096600B2 (en) 2010-12-20 2015-08-04 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
US8933066B2 (en) 2011-04-14 2015-01-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN103492389B (zh) 2011-04-21 2016-09-14 原真股份有限公司 用作激酶抑制剂的吡唑并[4,3-d]嘧啶
BR112014004971B1 (pt) 2011-09-02 2021-02-09 Incyte Holdings Corporation compostos heterociclilaminas, sua composição farmacêutica e seus usos
SG2014014450A (en) 2011-09-22 2014-09-26 Pfizer Pyrrolopyrimidine and purine derivatives
US8629150B2 (en) 2011-09-28 2014-01-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8697706B2 (en) 2011-10-14 2014-04-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8916702B2 (en) 2012-02-06 2014-12-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
BR112014030410A2 (pt) * 2012-06-07 2017-06-27 Hoffmann La Roche inibidores de pirazolopirimidona e pirazolopiridona de tanquirase
CN102827085A (zh) * 2012-09-17 2012-12-19 符爱清 2,4,5-三氯嘧啶化合物的制备方法
CN102952086B (zh) * 2012-09-28 2013-08-28 天津科创医药中间体技术生产力促进有限公司 一种2-吗啉基取代嘧啶类化合物的制备方法
CN102887860B (zh) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 4-氯-6-三氟甲基嘧啶类化合物的制备方法
US9422311B2 (en) 2012-10-18 2016-08-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2014060112A1 (fr) * 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines utiles en tant qu'inhibiteurs de kinases
JP5823657B1 (ja) 2012-11-08 2015-11-25 ファイザー・インク ドーパミンｄ１リガンドとしての複素芳香族化合物
NZ709360A (en) * 2012-12-20 2020-01-31 Ucb Biopharma Sprl Therapeutically active pyrazolo-pyrimidine derivatives
WO2014123892A1 (fr) 2013-02-07 2014-08-14 Bristol-Myers Squibb Company Molécules macrocycliques utilisées en tant qu'inhibiteurs de la pénétration du vhc
EP2953954B1 (fr) 2013-02-07 2017-11-15 Bristol-Myers Squibb Company Composés macrocycliques utilisés comme inhibiteurs de pénétration du vhc
US9745322B2 (en) 2013-03-07 2017-08-29 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN105143220B (zh) * 2013-03-07 2018-06-22 豪夫迈·罗氏有限公司 吡唑衍生物
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
TR201809417T4 (tr) 2013-05-02 2018-07-23 Hoffmann La Roche Cb2 reseptör agonistleri olarak purin türevleri.
RS56313B1 (sr) 2013-05-02 2017-12-29 Hoffmann La Roche Derivati pirolo[2,3-d]pirimidina kao agonisti cb2 receptora
JPWO2015005491A1 (ja) * 2013-07-12 2017-03-02 国立大学法人京都大学 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法
EP3057592B1 (fr) * 2013-10-18 2019-05-22 Indiana University Research and Technology Corporation Effecteurs d'assemblage de virus de l'hépatite b
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
CA2939219C (fr) * 2014-02-11 2023-02-28 Mitokinin Llc Compositions et procedes les utilisant pour le traitement de maladie neurodegenerative et mitochondriale
WO2015162515A1 (fr) 2014-04-25 2015-10-29 Pfizer Inc. Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1
WO2015162518A1 (fr) 2014-04-25 2015-10-29 Pfizer Inc. Composes hetero-aromatiques et leur utilisation comme ligands d1 de la dopamine
WO2015191677A1 (fr) 2014-06-11 2015-12-17 Incyte Corporation Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k
PL3244891T3 (pl) 2015-01-16 2022-12-27 The General Hospital Corporation Związki poprawiające splicing mRNA
SI3831833T1 (sl) 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
CN107922377A (zh) 2015-04-17 2018-04-17 美国印第安纳大学研究和技术公司 乙肝病毒组装效应子
WO2016183063A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Formes cristallines d'un inhibiteur de pi3k
WO2016183060A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases
WO2018049214A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
IL292977A (en) 2016-09-09 2022-07-01 Incyte Corp Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
WO2018049191A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridone en tant que modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
WO2018064135A1 (fr) * 2016-09-30 2018-04-05 Asana Biosciences, Llc Composés p2x3 et/ou p2x2/3 et méthodes associées
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CN114432318A (zh) 2017-02-20 2022-05-06 国立大学法人京都大学 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法
CA3067695A1 (fr) 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions et methodes les utilisant pour le traitement d'une maladie neurodegenerative et mitochondriale
CN107383014B (zh) * 2017-06-21 2019-04-30 南方医科大学 一种1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法和应用
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
WO2019051199A1 (fr) 2017-09-08 2019-03-14 Incyte Corporation Composés de 6-cyano-indazole utilisés en tant que modulateurs de kinase 1 progénitrices hématopoïétiques (hpk1)
BR112020009055A2 (pt) 2017-11-06 2020-11-03 Rapt Therapeutics, Inc. moduladores de receptor de quimiocina para tratamento de câncer positivo para vírus epstein barr
MD3755703T2 (ro) 2018-02-20 2022-10-31 Incyte Corp Derivați N-(fenil)-2-(fenil)pirimidin-4-carboxamidă și compuși înrudiți ca inhibitori HPK1 pentru tratarea cancerului
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
MA53726A (fr) 2018-09-25 2022-05-11 Incyte Corp Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
WO2020063636A1 (fr) * 2018-09-27 2020-04-02 苏州锐明新药研发有限公司 Composé de pyrazolopyrimidine et son procédé de préparation et son utilisation dans la préparation d'un médicament anticancéreux
CN110698432B (zh) * 2018-11-07 2023-02-03 中国医学科学院医药生物技术研究所 苯甲基哌嗪类化合物及其制备方法和在抗病毒中的应用
CN111170992B (zh) * 2018-11-12 2021-05-14 新发药业有限公司 一种5,6-二氢吡啶-2(1h)-酮衍生物的制备方法
US20220024891A1 (en) * 2018-12-04 2022-01-27 The Board Of Regents Of The University Of Texas System Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer
AU2020258017A1 (en) * 2019-04-18 2021-07-01 Université de Liège New pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling
CN110437253A (zh) * 2019-08-06 2019-11-12 复旦大学 含联苯结构的二芳基嘧啶并环化合物及其制备方法和用途
CA3147918A1 (fr) 2019-08-06 2021-02-11 Incyte Corporation Formes solides d'un inhibiteur d'hpk 1
EP4028133A1 (fr) 2019-09-13 2022-07-20 The United States of America, as represented by The Secretary, Department of Health and Human Services Inhibiteurs du récepteur de la tyrosine kinase pour le traitement de maladie ou de trouble sensible à la modulation de la protéine kinase
EP3800188A1 (fr) 2019-10-02 2021-04-07 Bayer AG Pyrazolopyrimidines substituées en tant qu'inhibiteurs d'irak4
US11939307B2 (en) 2019-11-29 2024-03-26 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Phenylmethyl-piperazine derivatives and antiviral uses thereof
CN111732575B (zh) * 2020-08-03 2020-12-11 北京鑫开元医药科技有限公司 一种n-(3-(嘧啶-2-基)苯基)苯磺酰胺类衍生物、药物组合物、制备方法及应用
JP2023552632A (ja) * 2020-12-11 2023-12-18 イルドン ファーマシューティカル カンパニー リミテッド アンドロゲン受容体及びホスホジエステラーゼ二重阻害剤としての新規化合物
CN113292452B (zh) * 2021-06-01 2023-03-24 山东京博生物科技有限公司 一种氰基乙酰胺的合成方法
CN113979945A (zh) * 2021-11-15 2022-01-28 湖北理工学院 一种制备3-氨基吡唑-4-甲酰胺半硫酸盐的新方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478830A (en) * 1992-05-29 1995-12-26 The Du Pont Merck Pharmaceutical Company Fused-ring heterocycles for the treatment of atherosclerosis
JP2004506737A (ja) * 2000-08-18 2004-03-04 アグーロン　ファーマシューティカルズ，インコーポレイテッド ピラゾール化合物、薬剤組成物、およびｅｒａｂまたはｈａｄｈ２活性の調節または阻害方法
WO2005121107A1 (fr) * 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Pyrazolopyrimidines
WO2006132460A1 (fr) * 2005-06-10 2006-12-14 Dong-A Pharmaceutical.Co., Ltd. Agent pour la prevention et le traitement des maladies du foie contenant un derive de la pyrazolopyrimidine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478830A (en) * 1992-05-29 1995-12-26 The Du Pont Merck Pharmaceutical Company Fused-ring heterocycles for the treatment of atherosclerosis
JP2004506737A (ja) * 2000-08-18 2004-03-04 アグーロン　ファーマシューティカルズ，インコーポレイテッド ピラゾール化合物、薬剤組成物、およびｅｒａｂまたはｈａｄｈ２活性の調節または阻害方法
WO2005121107A1 (fr) * 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Pyrazolopyrimidines
WO2006132460A1 (fr) * 2005-06-10 2006-12-14 Dong-A Pharmaceutical.Co., Ltd. Agent pour la prevention et le traitement des maladies du foie contenant un derive de la pyrazolopyrimidine

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

Also Published As

Publication number Publication date
WO2010118367A2 (fr) 2010-10-14

Similar Documents

Publication Publication Date Title
WO2010118367A3 (fr) Pyrimidines antivirales
WO2009091388A3 (fr) Triazines et composés associés présentant une activité antivirale, compositions et procédés associés
WO2011041713A3 (fr) Agents anti-viraux à base de pipérazinyle
MX2010009563A (es) Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
EP2853531A3 (fr) Composés antiviraux
MX2009012299A (es) Farmacos antivirales para el tratamiento o prevencion de la infeccion del dengue.
WO2008133753A3 (fr) Composés antiviraux
EA201390538A1 (ru) Противовирусные соединения
EA201000556A1 (ru) Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека)
WO2010081082A3 (fr) Dérivés de phosphoramidate de composés guanosine nucléoside pour le traitement d'infections virales
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
WO2012092484A3 (fr) Nucléosides puriques substitués, dérivés phosphoramidate et phosphorodiamidate pour le traitement d'infections virales
MY152971A (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
TW200720285A (en) Nucleoside compounds for treating viral infections
ATE475660T1 (de) Antivirale verbindungen
WO2008021936A3 (fr) Inhibiteurs du virus de l'hépatite c
WO2007041487A3 (fr) Peptides inhibiteurs d'infections virales
WO2011106992A8 (fr) Inhibiteurs de polymérase du virus de l'hépatite c ns5b
MX2011010905A (es) Compuestos antivirales.
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
WO2010055164A3 (fr) Nouveaux inhibiteurs de la réplication de flavivirus
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10762525

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10762525

Country of ref document: EP

Kind code of ref document: A2